Navigation Links
Leading Overseas Scientists Establish High-Tech Bio-Pharmaceutical Enterprise in Changzhou
Date:4/25/2008

Inactivated Rabies Vaccine for Animals to be Produced in Changzhou Hi-Tech

District, China

CHANGZHOU, China, April 25 /Xinhua-PRNewswire/ -- A project for producing inactivated rabies animal vaccines was recently launched in Changzhou National High-tech District, east China's Jiangsu Province. This is a new product developed by a team of leading overseas scientists. It is reported that it is the first time for China will produce this kind of high-tech inactivated vaccine. This vaccine is expected to replace less effective attenuated rabies living vaccines manufactured in China as well as the more expensive imported products.

In this project, major products of a newly-founded company, Changzhou Tongtai Biopharmaceutical Co., Ltd., will be produced. The technological team is under the leadership of Fu Zhenfang, professor of the veterinary institute of Georgia University, U.S. and a talented scientific and technological professional, who was introduced to Changzhou in 2007. With a total investment of USD 10 million, the production and sales value are expected to reach 200 million. In the first phase, a production base and research center for biological products for animal use will be built, focusing on the inactivated rabies vaccine. If production and sales targets for the first phase are fulfilled, a production base for the bird flu vaccine and FMD vaccine (Foot-and-Mouth Disease) will be constructed.

Rabies is a contagious disease, which can be prevented but cannot be cured, threatening the life of both humans and animals. The death rate is almost 100%. About 55000 lives are taken by this disease in Asia and Africa each year. China has a high occurrence area of rabies. According to statistics, from 2003 to 2005, the number of deaths caused by rabies in China is over 2500 on average, which is the highest in terms of number and rate of death of all infectious diseases. Rabies in China mainly infects dogs and cats. Therefore, in order to prevent rabies, preventive vaccination must be applied to dogs, cats and similar animals. However, the homemade attenuated rabies living animal vaccines that are in current, widespread use were long ago phased out in Europe and America. The World Health Organisation has also clearly expressed that they do not support its use because of its safety and questionable immunisation effects (especially as the source of the toxin used for manufacturing the attenuated living vaccine is showing signs of Atavism. The immunisation effect is also poor.) Therefore, there are serious hidden safety problems in the use of this vaccine.

Inactivated rabies vaccines represent the development trend of rabies preventative measures for animals, which has been widely applied in advanced countries. However due to its strict development conditions, there are no homemade supplies available in the domestic market. The imported inactivated vaccine is expensive, so it is difficult to be promoted extensively in China. Facing such a large dog-breeding market and the severe need for rabies prevention, it is imperative to produce homemade inactivated rabies. Therefore, the inactivated rabies vaccine produced by Changzhou Tongtai Bio- pharmaceutical Co., Ltd. will provide a safe, highly effective and low-cost option.

Professor Fu Zhenfang contributed his technology to the project and holds 65% of the shares. He is currently a professor working in the graduate school's pathology and epidemiology departments in the veterinary institute of Georgia University, US. As a famous virus specialist, he is an authoritative figure in the field of bio-products for animal use, especially in the research of rabies. His laboratory has mastered several manufacturing technologies, including inactivated rabies vaccine, parvovirus, hepatitis, canine distemper, and parainfluenza. They have independent intellectual property rights for core technologies of inactivated rabies vaccines for animals. Their technology takes the lead worldwide.

For more information, please contact:

Wang Zhongliang

Changzhou National High-tech District

Tel: +86-519-8512-7305 or +86-1309-2527-003

Fax: +86-519-8511-5905

Email: w_zongliang@sohu.com


'/>"/>
SOURCE National High-Tech District, Changzhou
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Avastin Used in Combination with Drugs from Bristol-Myers Squibb Has Advantages in Survival Rates Over the Current Sales-Leading Therapy for Advanced Ovarian Cancer
2. United BioSource Acquires Leading Publication Planning Software and Services Company
3. Leading Geneticist Francis Collins Named First Recipient of the Inamori Ethics Prize at Case Western Reserve University
4. CyberKnife Prostate Cancer Planning Study Published in Leading Radiation Oncology Journal
5. PAREXEL Appoints Leading Central Nervous System Experts to Its Global Clinical Pharmacology Business
6. Dragon retains leading investor relations firm
7. PAREXEL Appoints Leading Biopharmaceutical Marketing Expert Jacque Fisher to Medical Communications Services Executive Team
8. Halogen Customers Shape Industry-Leading Employee Performance and Talent Management Solution
9. PAREXEL to Present Leading Insights Regarding Key Industry Topics at 20th Annual Drug Information Association EuroMeeting
10. ZyGEM Appoints Leading Biotechnology Expert to Head Clinical Advisory Board
11. Cord Blood America CEO Matthew Schissler Interviewed by BIONOVA, Greeces Leading Biotech Magazine
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/28/2017)... Ann Arbor, Michigan (PRWEB) , ... March 28, ... ... company was awarded a Phase II Small Business Innovation Research (SBIR) grant from ... will receive approximately $750,000 over two years to develop a suite of BioGel™ ...
(Date:3/28/2017)... March 28, 2017 Summary This ... Enzo Biochem and its partnering interests and activities since 2010. ... provides an in-depth insight into the partnering activity of one ... demand company reports are prepared upon purchase to ensure inclusion ... The report will be delivered in PDF format ...
(Date:3/28/2017)... NAMUR , Belgium , March 28, ... of VolitionRx Limited (NYSE MKT: VNRX), today announced the engagement ... of DVD Associates, LLC, as a strategic consultant. Dr. ... in identifying and securing non-dilutive funding in the ... the United States . Dr. Vollmer Dahlke ...
(Date:3/28/2017)... 28, 2017  Viking Therapeutics, Inc. ("Viking") (NASDAQ: VKTX), ... novel therapies for metabolic and endocrine disorders, today announced ... Ph.D., will deliver a corporate presentation at H.C. Wainwright ... being held April 3, 2017 at the St. Regis ... this presentation are as follows: ...
Breaking Biology Technology:
(Date:3/20/2017)... At this year,s CeBIT Chancellor Dr. Angela ... The Chancellor came to the DERMALOG stand together with the Japanese Prime ... partner country. At the largest German biometrics company the two government leaders ... iris recognition as well as DERMALOG´s multi-biometrics system.   ... ...
(Date:3/9/2017)... , Australia , March 9, ... study data at the prestigious World Lung Imaging Workshop ... Andreas Fouras , was invited to deliver the ... pulmonary medicine. This globally recognised event brings together leaders ... share the latest developments in lung imaging. ...
(Date:3/6/2017)... , March 6, 2017 Mintigo ... technology, today announced Predictive Sales Coach TM , ... actionable sales intelligence into Salesforce. This unique AI ... their sales organizations with deep knowledge of their ... for intelligent engagement. Predictive Sales Coach extends Mintigo,s ...
Breaking Biology News(10 mins):